loader
Page is loading...
OVERVIEW

William R. Boudreaux
Partner

Ann Arbor

2723 S. State Street
Suite 150
Ann Arbor, MI 48104

P 734-489-8003

F 734-489-8002

OVERVIEW

William R. Boudreaux
Partner

Ann Arbor

2723 S. State Street
Suite 150
Ann Arbor, MI 48104

P 734-489-8003

F 734-489-8002

A recognized leader in the life sciences space, Bill Boudreaux is known for his thoughtful, thorough approach and his ability to anticipate client needs. He is an experienced pharmaceutical patent lawyer, bringing more than 20 years of experience from both in-house and private practice settings.

OVERVIEW

A recognized leader in the life sciences space, Bill Boudreaux is known for his thoughtful, thorough approach and his ability to anticipate client needs. He is an experienced pharmaceutical patent lawyer, bringing more than 20 years of experience from both in-house and private practice settings.

Bill’s extensive in-house experience at major pharmaceutical companies gives him a unique perspective, allowing him to provide a broad range of biotech and pharma clients ranging from Fortune Global 500 companies to startups, with practical, business-focused advice. 

Whether providing advice to in-house counsel or business associates, Bill understands the importance of delivering legal advice in a distilled, business-focused way. In-house counsel appreciate that he has literally been in their shoes because it is rare to find someone who understands the various aspects of their jobs and the associated legal issues, pressures and relational dynamics.

Bill has extensive experience in global patent portfolio creation and management, pharmaceutical patent life-cycle planning and IP due diligence. He is also skilled in assisting clients with freedom-to-operate studies, due diligence reviews, infringement and validity studies, and strategy and support for Hatch-Waxman litigation.

While at Eli Lilly and Co. and Pfizer, Bill was primary patent counsel for several late-stage and post-launch drug products, including four blockbuster drugs.

With his former firm, Bill was co-chair of the patent prosecution, biotechnology and pharmaceutical practice groups and served on the firm’s board of directors and executive committee. 

Professional and Community Involvement

Member, Intellectual Property Owners Association (IPO)

Member, IPO Pharmaceutical Issues Committee

Member, American Intellectual Property Law Association

Former member, IPO U.S. Patent Law (U.S.) Committee

Former member, IPO Hatch Waxman Committee

Former member, IPO Patent Office Practice (U.S.) Committee

Honors

Leading Lawyers Network, 2014-2016

LMG Life Sciences Life Science Star, 2012-2019

EXPERIENCE
Presentations
  • “Patent Prosecution and the Newly Implemented USPTO (AIA) Regulations” Midwest Intellectual Property Symposium, Indianapolis, Indiana, Nov. 15, 2012
  • "An Industry Perspective on Implementation of the AIA, New PTO Proceedings, and Their Collective Impact on Life Cycle Management," American Conference Institute's Maximizing Pharmaceutical Patent Life Cycles, New York City, Oct. 10, 2012
  • "The post-AIA World: Factoring the Impact of Patent Reform into Biosimilars Prosecution and Litigation Strategies," American Conference Institute's 3rd Advanced Forum on Biosimilars, New York City, May 23, 2012
  • “Pharmaceutical Patent Life Cycle Management – a US Perspective,” D. Young & Co. Life Sciences Patent Seminar, Copenhagen, Denmark, Oct. 4, 2010
INSIGHTS AND EVENTS
Trending Connect
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to use cookies.